Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringem
January 25 2008 - 12:39PM
PR Newswire (US)
NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX), Forest Laboratories Holdings, Ltd., Merz Pharma
GmbH & Co. KgaA, and Merz Pharmaceuticals GmbH announced that
they have filed a second lawsuit in the U.S. District Court for the
District of Delaware against additional companies for infringement
of U.S. Patent No. 5,061,703 (the '703 patent), which relates to
Forest's Namenda(R) product. The defendants named in the lawsuit
include Dr. Reddy's Laboratories Limited, Genpharm Inc., Interpharm
Inc., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories Limited, Sun
India Pharmaceutical Industries Limited, and related companies and
subsidiaries thereof. The '703 patent expires in April 2010. Forest
has applied for patent term extension which, if granted, would
extend the '703 patent until September 2013. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) As
previously reported, Forest and Merz had received notification from
several companies that they had filed Abbreviated New Drug
Applications with Paragraph IV certifications to obtain approval to
market generic versions of Namenda and commenced an action in
patent infringement in the U.S. District Court in Delaware against
such filers. Except for the historical information contained
herein, this release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform act of 1995.
These statements involve a number of risks and uncertainties,
including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to
time in each of Forest Laboratories' Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and any subsequent SEC filings.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
http://photoarchive.ap.org/ DATASOURCE: Forest Laboratories, Inc.
CONTACT: Charles E. Triano, Vice President - Investor Relations,
Forest Laboratories, Inc., +1-212-224-6714, Web site:
http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024